Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

Choosing between the diversified stability of Johnson & Johnson (NYSE:JNJ) and the rapid growth trajectory of Eli Lilly & Co (NYSE:LLY) is a primary consideration for many healthcare investors in 2026.

Johnson & Johnson provides a broad foundation through drugs and medical devices, while Eli Lilly & Co focuses on blockbuster treatments for diabetes and obesity. They are being compared because they represent two different paths to success within the healthcare stocks universe, appealing to either value-oriented or growth-seeking investors.

The case for Johnson & Johnson

Johnson & Johnson operates through two primary segments, focusing on innovative medicine and its diverse portfolio of medical device stocks. The company reaches a global audience of hospitals, wholesalers, and healthcare professionals while collaborating with partners like AbbVie (NYSE:ABBV) to co-commercialize key oncology treatments. These strategic alliances and internal research efforts allow it to maintain a dominant presence in immunology, neuroscience, and cardiovascular health.

In FY 2025, revenue reached roughly $94 billion, a 6% increase from the prior period. The company reported a net income of nearly $27 billion for the year. This resulted in a net margin of approximately 29%, indicating the percentage of revenue converted into actual profit after taxes and costs. The significant increase in net income compared to the prior year was driven by expanding operational efficiency and higher demand for key medications.

As of its December 2025 balance sheet, the debt-to-equity ratio was nearly 0.6x. This metric compares total debt to shareholder equity, suggesting the company maintains a manageable level of borrowing. The current ratio stands at approximately 1.0x, which means the company has exactly enough short-term assets to cover its immediate liabilities. Free cash flow, calculated as operating cash flow minus capital expenditures, reached nearly $19.7 billion in the same period.

The case for Eli Lilly & Co

Eli Lilly focuses its research on cardiometabolic health, oncology, and neuroscience, with a massive emphasis on treatments for diabetes and obesity. It distributes products globally through major wholesalers such as McKesson Corp (NYSE:MCK), Cencora Corp (NYSE:COR), and Cardinal Health Inc (NYSE:CAH). The company has also expanded its reach through LillyDirect, a digital platform that provides medicines directly to patients via third-party pharmacies.

In FY 2025, revenue reached about $65.2 billion, representing an impressive 45% growth compared to the prior year. This rapid expansion translated into a net income of approximately $20.6 billion. The company achieved a net margin of nearly 32%, which measures how much of every dollar in sales remains as profit after all expenses are paid. Net income nearly doubled year over year, supported by the success of its newest pharmaceutical launches.

As of its December 2025 balance sheet, the current ratio was nearly 1.6x, indicating a strong ability to cover short-term obligations with liquid assets. The debt-to-equity ratio reached roughly 1.6x, which measures the relationship between total debt and the equity provided by shareholders. Free cash flow for the year was nearly $9.0 billion. This figure represents the cash remaining after the business pays for the maintenance and expansion of its physical assets.

Risk profile comparison

Johnson & Johnson faces intense competition from rivals of all sizes, especially as patent expirations invite generic alternatives. It also manages significant legal risks, specifically product liability proceedings related to talc-containing products. Furthermore, management is navigating the execution risks of separating its orthopedics business while complying with price-reduction mandates from the Inflation Reduction Act.

Eli Lilly depends heavily on a small group of cardiometabolic products, which generated roughly 82% of revenue in 2025. This concentration leaves the business vulnerable to intellectual property challenges and pricing pressure from government payers. Additionally, reliance on single-source suppliers and third-party manufacturers creates potential supply chain bottlenecks in a highly regulated global environment.

Valuation comparison

Johnson & Johnson appears as the more conservative value play, whereas Eli Lilly carries a much higher premium reflecting its aggressive growth trajectory.

Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

Johnson & Johnson is an overlooked behemoth compared with faster-growing biotech companies. The business has 28 products and platforms that generate more than $1 billion in annual revenue. Its pharmaceuticals arm, Innovative Medicine, has received two FDA approvals this year and has two more approved drug product launches in the E.U. and the U.S. The Innovative Medicine division accounts for 65% of JNJ's annual revenue and appears to have a robust pipeline beyond the pending products. MedTech, its other arm, sells a wide range of healthcare products, including wound care, surgical instruments and implants, hip and knee replacements, and spinal implants. The recent buy of Atraverse Medical bolsters that business. Revenue for JNJ is expected to rise to $101 billion in the current fiscal year.

Eli Lilly, meanwhile, is riding a wave of success with its GLP-1 drugs Zepbound for weight loss and Mounjaro, which is the same drug for diabetes control. There is still plenty of growth left in the treatment, and that is expected to power revenue up as high as 30% in 2026, to $85.2 billion, with close to $31 billion in net income. Its next weight-loss drug, Retatrutide, is hotly anticipated for its triple-agonist approach, which is expected to exceed the weight-loss results of Zepbound. The company is also targeting less affluent customers with a lower-cost GLP pill called Foundayo, which it sells directly to consumers.

Besides GLP-1s, Lilly is working on a small interfering RNA therapeutic targeting lipoprotein(a) for the prevention of atherosclerotic cardiovascular disease in patients with elevated lipoprotein(a) levels. Analysts believe it will be a blockbuster ($1 billion or more lifetime revenue) if approved.

JNJ is a healthcare stalwart, but it does not have the GLP-1 mojo that Eli Lilly has been riding. Lilly may come at a premium, as shown by its higher P/S and forward P/E ratios, but it brings with it exceptional growth. Long-term investors would do well to pay a little extra now for growth for years to come.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Eli Lilly. The Motley Fool recommends Johnson & Johnson and McKesson. The Motley Fool has a disclosure policy.